Instruction for use: Salben

Active substance Salbutamol

ATX Code R03CC02 Salbutamol

Pharmacotherapeutic group:

Beta-adrenergic agonist

The nosological classification (ICD-10)

J44 Other chronic obstructive pulmonary disease

Allergic bronchitis, Bronchitis asthma, Asthmatic bronchitis, wheeze bronchitis, Bronchitis is an obstructive, bronchi disease, Shortness of sputum in acute and chronic respiratory diseases, Cough in inflammatory diseases of the lung and bronchus, Reversible airflow obstruction, Reversible obstructive airway disease, Obstructive bronchitis disease, Obstructive lung disease, Obstructive bronchitis, Spastic bronchitis, Chronic lung disease, Chronic nonspecific lung diseases, Chronic obstructive pulmonary disease, Chronic obstructive bronchitis, Chronic obstructive airway disease, Chronic obstructive pulmonary disease, Restrictive lung pathology

J45 Asthma

Asthma physical effort, status asthmaticus, Bronchial asthma, Asthma lung flow, Bronchial asthma with obstruction of sputum discharge, Bronchial asthma heavy currents, Bronchial asthma physical effort, hypersecretory asthma, Hormone-dependent form of bronchial asthma, Relief of asthma attacks in bronchial asthma, Non-allergic asthma, nocturnal asthma, Exacerbation of asthma, Asthma attacks, Endogenous forms of asthma, Night asthma, Cough with bronchial asthma

Structure and Composition

The powder for inhalation dose 1 dose

200 micrograms salbutamol

Sodium Benzoate 9.8 mg

in inhalers "tsiklohalera" at doses of 100 or 200; in a cardboard box 1 pc.

Characteristic

Crystalline powder white or nearly white.

pharmachologic effect

bronchodilatory.

It stimulates the beta 2-adrenergic receptors. It relaxes the smooth muscles of the bronchi, activates the function of the ciliated epithelium of the mucous membrane of the trachea and bronchi and enhances mucociliary transport, inhibits the release of inflammatory mediators from mast cells and basophils; It has antifungal (fungicidal) and expectorant action (sodium benzoate).

pharmacodynamics

Bronchodilator effect occurs within 4-5 minutes after inhalation, reaching a peak after 40-60 minutes. Duration -. 4-5 hours reduces the frequency and severity of symptoms such as cough, shortness of breath, attacks of breathlessness, feeling of tightness in the chest.

Indications

Bronchial asthma (mild asthma), diseases accompanied by reversible airflow obstruction, including chronic obstructive bronchitis (prevention and treatment).

Contraindications

Hypersensitivity, decompensated forms of diseases of the cardiovascular system, liver, kidneys, expressed heart rhythm disorders.

Side effects

Anxiety, skeletal muscle tremor, palpitations, sleep disturbance.

Interaction

Compatible with asthma medication other pharmacological groups (glucocorticoids, Membrane stabilizers, antihistamines, expectorants, mucolytics, anticholinergics, xanthine).

Dosing and Administration

Inhalation using individual portable inhaler "tsiklohalera".

Relief of attacks: 1-2 doses per reception (200-400 g).

Prevention and treatment of asthma: mild - 1-2 dose 1-4 times a day, moderate - at the same dosage in combination with other antiasthmatic agents.

Prevention of asthma of physical effort: 1-2 doses at the reception for 20-30 minutes to load.

Storage conditions

In a dry, dark place at a temperature no higher than 25 ° C.

Keep out of the reach of children.

The shelf life of the drug Salben®

3 years.

Do not use beyond the expiration date printed on the package.